WOVEN-PLANET-HOLDINGS
2.6.2022 04:02:12 CEST | Business Wire | Press release
TOYOTA MOTOR CORPORATION (“Toyota”) and its subsidiary, Woven Planet Holdings, Inc. ("Woven Planet"), have developed a working prototype of its portable hydrogen cartridge. This cartridge design will facilitate the everyday transport and supply of hydrogen energy to power a broad range of daily life applications in and outside of the home. Toyota and Woven Planet will conduct Proof of Concept (“PoC”) trials in various places, including Woven City, a human-centered smart city of the future currently being constructed in Susono City, Shizuoka Prefecture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005081/en/
Toyota and Woven Planet are studying a number of viable pathways to carbon neutrality and consider hydrogen to be a promising solution. Hydrogen has significant advantages. Zero Carbon Dioxide (CO2) is emitted when hydrogen is used. Furthermore, when hydrogen is produced using renewable energy sources such as wind, solar, geothermal, and biomass, CO2 emissions are minimized during the production process as well. Hydrogen can be used to generate electricity in fuel cell systems and can also be used as a combustion fuel.
Together with ENEOS Corporation, Toyota and Woven Planet are working to build a comprehensive hydrogen-based supply chain aimed at expediting and simplifying production, transport, and daily usage. These trials will focus on meeting the energy needs of Woven City residents and those living in its surrounding communities.
Benefits of Using Hydrogen Cartridges
-
Portable, affordable, and convenient energy that makes it possible to bring hydrogen to where people live, work, and play without the use of pipes
- Prototype dimensions: 400mm (16") in length x 180mm (7") in diameter
- Target weight: 5 kg (11lbs)
- Swappable for easy replacement and quick recharging
- Volume flexibility allows for a broad variety of daily use applications*2
- Small-scale infrastructure can meet energy needs in remote and non-electrified areas and be swiftly dispatched in the case of a disaster
Next Steps for the Hydrogen Cartridge
Today most hydrogen is generated from fossil fuels and used for industrial purposes such as fertilizer production and petroleum refining. To use hydrogen as an energy source in our homes and daily life, the technology must meet different safety standards and be adjusted to new environments. In the future, we expect hydrogen will be generated with very low carbon emissions and used in a wider variety of applications. The Japanese government is working on a range of studies to promote the safe early adoption of hydrogen and Toyota and its business partners are excited to offer cooperation and support.
Our goal is to help hydrogen become commonplace by making this clean form of energy safe, convenient, and affordable. By establishing the underlying supply chain, we hope to facilitate the flow of a larger volume of hydrogen and fuel more applications. Woven City will explore and test an array of energy applications using hydrogen cartridges including mobility, household applications, and many future possibilities we have yet to imagine. Together with inventors and those living within and around Woven City, we will continue to advance mobility over time by constantly developing more practical applications for hydrogen cartridges. In future Woven City demonstrations, we will continue to improve the hydrogen cartridge itself, making it increasingly easy to use and improving the energy density.
The ultimate goal of this project is to realize a carbon-neutral society where everyone can access clean energy, first in Japan and then throughout the world. Toyota and Woven Planet aim to develop best practices for incorporating clean hydrogen energy into daily life by conducting human-centered demonstrations in and around Woven City. These real-life experiences will help us learn how to best transform hydrogen into a familiar, well-used, and well-loved form of energy.
The portable hydrogen cartridge prototype will be showcased at Super Taikyu Series 2022 Round 2 at Fuji SpeedWay from June 3 to 5, 2022*3 . Our showcase is geared toward teaching people about how hydrogen energy works and helping them imagine the countless ways hydrogen can become a useful part of their daily lives.
*1 Specifications and design are subject to change. The target weight of a full tank (5kg) excludes a valve and protector. Multiple types of receptacles will be considered in the future based on further application research over time.
*2 When electricity is generated by a typical FC system, one hydrogen cartridge is assumed to generate enough electricity to operate a typical household microwave for approximately 3-4 hours (based on the assumption of using a future iteration, high-pressure hydrogen tank with an electricity output of approximately 3.3 kWh/unit).
*3 Our showcase will be on June 4 and June 5 only.
Video Links
English: https://youtu.be/poYJCJR-WRo
Japanese: https://youtu.be/85_6eMJofuY
About Toyota Motor Corporation
Toyota Motor Corporation (Toyota) (NYSE: TM) is the global mobility company that introduced the Prius hybrid-electric car in 1997 and the first mass-produced fuel cell sedan, Mirai, in 2014. Headquartered in Toyota City, Japan, Toyota has been making cars since 1937. Today, Toyota proudly employs 370,000 employees in communities around the world. Together, they build around 10 million vehicles per year in 28 countries and regions, from mainstream cars and premium vehicles to mini-vehicles and commercial trucks, and sell them in more than 170 countries and regions under the brands Toyota, Lexus, Daihatsu and Hino.
For more information, please visit https://global.toyota/en
About Woven Planet
Woven Planet is building the safest mobility in the world. A subsidiary of Toyota, Woven Planet innovates and invests in new technologies, software, and business models that transform how we live, work and move. With a focus on automated driving, smart cities, robotics and more, Woven Planet builds on Toyota's legacy of trust to deliver secure, connected, reliable, and sustainable mobility solutions for all.
Learn more at https://www.woven-planet.global/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom